TY - JOUR AU - Hay, M. AU - Thomas, D. W. AU - Craighead, J. L. AU - Economides, C. AU - Rosenthal, J. PY - 2014 DA - 2014// TI - Clinical development success rates for investigational drugs JO - Nat Biotechnol VL - 32 UR - https://doi.org/10.1038/nbt.2786 DO - 10.1038/nbt.2786 ID - Hay2014 ER - TY - JOUR AU - Nie, L. AU - Rubin, E. H. AU - Mehrotra, N. AU - Pinheiro, J. AU - Fernandes, L. L. AU - Roy, A. PY - 2016 DA - 2016// TI - Rendering the 3 + 3 design to rest: more efficient approaches to oncology dose-finding trials in the era of targeted therapy JO - Clin Cancer Res VL - 22 UR - https://doi.org/10.1158/1078-0432.CCR-15-2644 DO - 10.1158/1078-0432.CCR-15-2644 ID - Nie2016 ER - TY - JOUR AU - Venkatakrishnan, K. AU - Friberg, L. E. AU - Ouellet, D. AU - Mettetal, J. T. AU - Stein, A. AU - Trocóniz, I. F. PY - 2015 DA - 2015// TI - Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities JO - Clin Pharmacol Ther VL - 97 UR - https://doi.org/10.1002/cpt.7 DO - 10.1002/cpt.7 ID - Venkatakrishnan2015 ER - TY - STD TI - Hodi FS, Kluger HM, Sznol M, Carvajal RD, Lawrence DP, Atkins MB, et al. Long-term survival of ipilimumab-naïve patients with advanced melanoma treated with nivolumab in a phase 1 trial. Presented at the Society for Melanoma Research 11th Annual Meeting. Zurich; 2014. ID - ref4 ER - TY - JOUR AU - Feng, Y. AU - Roy, A. AU - Masson, E. AU - Chen, T. T. AU - Humphrey, R. AU - Weber, J. S. PY - 2013 DA - 2013// TI - Exposure-response relationships of the efficacy and safety of ipilimumab in patients with advanced melanoma JO - Clin Cancer Res VL - 19 UR - https://doi.org/10.1158/1078-0432.CCR-12-3243 DO - 10.1158/1078-0432.CCR-12-3243 ID - Feng2013 ER - TY - JOUR AU - Feng, Y. AU - Masson, E. AU - Dai, D. AU - Parker, S. M. AU - Berman, D. AU - Roy, A. PY - 2014 DA - 2014// TI - Model-based clinical pharmacology profiling of ipilimumab in patients with advanced melanoma JO - Br J Clin Pharmacol VL - 78 UR - https://doi.org/10.1111/bcp.12323 DO - 10.1111/bcp.12323 ID - Feng2014 ER - TY - STD TI - Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23. ID - ref7 ER - TY - JOUR AU - Topalian, S. L. AU - Hodi, F. S. AU - Brahmer, J. R. AU - Gettinger, S. N. AU - Smith, D. C. AU - McDermott, D. F. PY - 2012 DA - 2012// TI - Safety, activity, and immune correlates of anti-PD-1 antibody in cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1200690 DO - 10.1056/NEJMoa1200690 ID - Topalian2012 ER - TY - JOUR AU - Robert, C. AU - Long, G. V. AU - Brady, B. AU - Dutriaux, C. AU - Maio, M. AU - Mortier, L. PY - 2015 DA - 2015// TI - Nivolumab in previously untreated melanoma without BRAF mutation JO - N Engl J Med VL - 372 UR - https://doi.org/10.1056/NEJMoa1412082 DO - 10.1056/NEJMoa1412082 ID - Robert2015 ER - TY - JOUR AU - Brahmer, J. AU - Reckamp, K. L. AU - Baas, P. AU - Crinò, L. AU - Eberhardt, W. E. AU - Poddubskaya, E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1504627 DO - 10.1056/NEJMoa1504627 ID - Brahmer2015 ER - TY - JOUR AU - Borghaei, H. AU - Paz-Ares, L. AU - Horn, L. AU - Spigel, D. R. AU - Steins, M. AU - Ready, N. E. PY - 2015 DA - 2015// TI - Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1507643 DO - 10.1056/NEJMoa1507643 ID - Borghaei2015 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. AU - George, S. AU - Hammers, H. J. AU - Srinivas, S. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - BOOK PY - 2003 DA - 2003// TI - Common Terminology Criteria for Adverse Events (CTCAE), Version 3.0 PB - National Cancer Institute CY - Bethesda ID - ref13 ER - TY - JOUR AU - Eisenhauer, E. A. AU - Therasse, P. AU - Bogaerts, J. AU - Schwartz, L. H. AU - Sargent, D. AU - Ford, R. PY - 2009 DA - 2009// TI - New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) JO - Eur J Cancer VL - 45 UR - https://doi.org/10.1016/j.ejca.2008.10.026 DO - 10.1016/j.ejca.2008.10.026 ID - Eisenhauer2009 ER - TY - JOUR AU - Brahmer, J. R. AU - Drake, C. G. AU - Wollner, I. AU - Powderly, J. D. AU - Picus, J. AU - Sharfman, W. H. PY - 2010 DA - 2010// TI - Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.7609 DO - 10.1200/JCO.2009.26.7609 ID - Brahmer2010 ER - TY - STD TI - Agrawal A, Feng Y, Kollia G, Saeger S, Ullmann M, McDonald D, et al. Clinical pharmacokinetics (PK) of BMS-936558, a fully human anti-PD-1 monoclonal antibody. J Clin Oncol. 2012;30(15 suppl). Abstract TPS2622. ID - ref16 ER - TY - JOUR AU - Wang, Y. AU - Sung, C. AU - Dartois, C. AU - Ramchandani, R. AU - Booth, B. P. AU - Rock, E. PY - 2009 DA - 2009// TI - Elucidation of relationship between tumor size and survival in non-small-cell lung cancer patients can aid early decision making in clinical drug development JO - Clin Pharmacol Ther VL - 86 UR - https://doi.org/10.1038/clpt.2009.64 DO - 10.1038/clpt.2009.64 ID - Wang2009 ER - TY - JOUR AU - Gupta, D. AU - Lis, C. G. PY - 2010 DA - 2010// TI - Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature JO - Nutr J VL - 9 UR - https://doi.org/10.1186/1475-2891-9-69 DO - 10.1186/1475-2891-9-69 ID - Gupta2010 ER - TY - JOUR AU - Brezski, R. J. AU - Jordan, R. E. PY - 2010 DA - 2010// TI - Cleavage of IgGs by proteases associated with invasive diseases: an evasion tactic against host immunity JO - MAbs VL - 2 UR - https://doi.org/10.4161/mabs.2.3.11780 DO - 10.4161/mabs.2.3.11780 ID - Brezski2010 ER - TY - JOUR AU - Gettinger, S. N. AU - Horn, L. AU - Gandhi, L. AU - Spigel, D. R. AU - Antonia, S. J. AU - Rizvi, N. A. PY - 2015 DA - 2015// TI - Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.3708 DO - 10.1200/JCO.2014.58.3708 ID - Gettinger2015 ER - TY - JOUR AU - McDermott, D. F. AU - Drake, C. G. AU - Sznol, M. AU - Choueiri, T. K. AU - Powderly, J. D. AU - Smith, D. C. PY - 2015 DA - 2015// TI - Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.58.1041 DO - 10.1200/JCO.2014.58.1041 ID - McDermott2015 ER - TY - STD TI - Feng Y, Masson E, Williams D, Song J, Cuillerot J-M, Roy A. Characterization of the relationship between ipilimumab exposure, tumor size, and survival in previously treated non-small cell lung cancer patients. Presented at the 113th American Society for Clinical Pharmacology and Therapeutics Annual Meeting. National Harbor, Maryland; 2012. Abstract 253. ID - ref22 ER -